LENZ Therapeutics (LENZ) Free Cash Flow Growth (1y) (2021 - 2026)
LENZ Therapeutics (LENZ) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | LENZ Therapeutics | 179.65 Mn | -78.73 Mn | 825,000.00 | -107.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.82% |
| Dec 31, 2025 | -249.37% |
| Sep 30, 2025 | 15.84% |
| Jun 30, 2025 | 26.55% |
| Mar 31, 2025 | 32.49% |
| Dec 31, 2024 | 56.00% |
| Sep 30, 2024 | 16.72% |
| Jun 30, 2024 | -16.93% |
| Mar 31, 2024 | -86.95% |
| Dec 31, 2023 | 10.58% |
| Sep 30, 2023 | 43.42% |
| Jun 30, 2023 | 42.47% |
| Mar 31, 2023 | 47.77% |
| Dec 31, 2022 | -41.49% |
| Sep 30, 2022 | -21.42% |
| Jun 30, 2022 | -61.40% |
| Mar 31, 2022 | -191.13% |
| Dec 31, 2021 | -181.73% |
| Sep 30, 2021 | -525.24% |